2024-10-19 03:29:07,433 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:29:07,435 - INFO - Run 0:
Given the information and applying the superforecasting methodology, here is my analysis for this specific forecasting question:

1. **Reference and Comparison Classes**: Historically, declarations of high public health risk levels by the CDC have been reserved for diseases with widespread current outbreaks within the U.S. or significant global threats with imminent risk to the U.S. Thus far, there has been no indication of mpox being widespread in the U.S.

2. **Current Status and Evidence**: The CDC's most recent assessment labeled the risk of mpox to the general U.S. population as "VERY LOW" with moderate confidence. There's no immediate indication that this will change drastically in the near future, considering how localized the outbreak is to Africa, with limited spread and impact reported in Europe and other regions.

3. **International Alerts and Reactions**: The WHO has declared a Public Health Emergency of International Concern for mpox, which might influence the U.S.'s future risk assessments. However, declarations by the WHO don't automatically imply an increased risk assessment by the CDC unless there's substantial evidence of potential spread to the U.S.

4. **Current Trends and Causal Forces**: Despite reports of increased cases in Africa and a new, more virulent clade, the transmission appears contained with low transmission risk to the U.S. The U.S. epidemiological measures and vaccine stockpiles also suggest robust preparedness that could prevent any significant outbreak.

5. **Balancing Inside and Outside Views**: While international attention is on mpox, the CDC assessments focus specifically on risks to the U.S, and this often results in more conservative or lower risk assessments domestically, unless there's evidence of rapid spread within the U.S.

6. **Superforecasting Commandments**: I'm considering potential changes in the risk level over time but balancing optimism (U.S. preparedness) with caution (global rising cases), ultimately requiring a moderate increase in probability from very low due to the WHO's concerns.

All these factors lead to a conclusion that while there's a slight chance of it exceeding "High" by October 1, 2024, it remains relatively low based on the U.S. focus and preventive measures.

My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.

2024-10-19 03:29:28,049 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:29:28,049 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:29:28,049 - INFO - Run 1:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "High" before October 1, 2024, I will break the problem into manageable parts, utilizing previous superforecasting principles and available information.

**Step 1: Reference Class Forecasting**

Firstly, I identify base rates of similar events: assessing past CDC assessments of disease risk levels and frequency of elevation to "High" risk. Historically, major disease outbreaks or significant increases in transmissibility are the most common triggers for raising a CDC risk level to "High" or above.

- The CDC has consistently assessed risks to the general population in line with global disease dynamics and specific epidemiological factors.
- Given that the current CDC assessment is "VERY LOW," a shift to "High" or above would historically require substantial, concrete threats to domestic safety from the disease.

**Step 2: Current Situation Analysis**

The following are key points extracted from the news articles and background on the current mpox situation:

- There is a declared public health emergency in Africa due to a new, more virulent mpox strain, specifically in the Democratic Republic of Congo.
- The WHO has declared mpox a global public health emergency, but the transmission to and within the US remains limited.
- The latest assessment by the CDC rated the risk to the US general population as "VERY LOW," suggesting that they see no immediate threat.
- Primary risks for the US are related to individuals with specific risk factors or those traveling from affected regions, not the general US population yet.
- The outbreak in Africa, while severe, has not shown evidence of significant spread into North America, nor into the general population.

**Step 3: Weighing Evidence**

Positive Resolution Factors:
- If the outbreak in Africa spreads further and becomes notably widespread in countries with high travel volume to/from the US or if there are direct cases in the US, the risk level could increase. 
- A significant rise in uncontrolled mpox cases in the US could also lead to a higher risk assessment.

Negative Resolution Factors:
- The current risk to the US population is assessed as very low and based on the latest news articles, there hasn't been significant change domestically.
- Comprehensive measures in place, public health responses in the US, and available vaccines could help manage potential outbreaks, mitigating any need for increased risk assessment.

Considering the lack of impactful changes that might cause the CDC to significantly alter its risk assessment, coupled with the historical context of risk reviews, the probability of this specific shift (to above "High") within the given timeframe is relatively low.

**My Prediction: Between 2.50% and 7.50%, but 4.00% being the most likely. Probability: 4.00%.**

2024-10-19 03:29:28,049 - INFO - Run 1:
To forecast whether the CDC's assessment of the risk posed by mpox to the US general public will exceed "High" before October 1, 2024, I will break the problem into manageable parts, utilizing previous superforecasting principles and available information.

**Step 1: Reference Class Forecasting**

Firstly, I identify base rates of similar events: assessing past CDC assessments of disease risk levels and frequency of elevation to "High" risk. Historically, major disease outbreaks or significant increases in transmissibility are the most common triggers for raising a CDC risk level to "High" or above.

- The CDC has consistently assessed risks to the general population in line with global disease dynamics and specific epidemiological factors.
- Given that the current CDC assessment is "VERY LOW," a shift to "High" or above would historically require substantial, concrete threats to domestic safety from the disease.

**Step 2: Current Situation Analysis**

The following are key points extracted from the news articles and background on the current mpox situation:

- There is a declared public health emergency in Africa due to a new, more virulent mpox strain, specifically in the Democratic Republic of Congo.
- The WHO has declared mpox a global public health emergency, but the transmission to and within the US remains limited.
- The latest assessment by the CDC rated the risk to the US general population as "VERY LOW," suggesting that they see no immediate threat.
- Primary risks for the US are related to individuals with specific risk factors or those traveling from affected regions, not the general US population yet.
- The outbreak in Africa, while severe, has not shown evidence of significant spread into North America, nor into the general population.

**Step 3: Weighing Evidence**

Positive Resolution Factors:
- If the outbreak in Africa spreads further and becomes notably widespread in countries with high travel volume to/from the US or if there are direct cases in the US, the risk level could increase. 
- A significant rise in uncontrolled mpox cases in the US could also lead to a higher risk assessment.

Negative Resolution Factors:
- The current risk to the US population is assessed as very low and based on the latest news articles, there hasn't been significant change domestically.
- Comprehensive measures in place, public health responses in the US, and available vaccines could help manage potential outbreaks, mitigating any need for increased risk assessment.

Considering the lack of impactful changes that might cause the CDC to significantly alter its risk assessment, coupled with the historical context of risk reviews, the probability of this specific shift (to above "High") within the given timeframe is relatively low.

**My Prediction: Between 2.50% and 7.50%, but 4.00% being the most likely. Probability: 4.00%.**

2024-10-19 03:29:46,333 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:29:46,333 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:29:46,333 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:29:46,334 - INFO - Run 2:
To determine the likelihood of the CDC's assessment of mpox risk exceeding "High" for the US general public before October 1, 2024, let's evaluate the following factors:

1. **Current CDC Risk Level**: As of the latest CDC assessment on August 14, 2024, the overall risk to the general US population is "VERY LOW." There is no immediate indication that the CDC will raise this assessment to "High" based solely on US-specific factors.

2. **WHO Global Health Emergency Declaration**: The WHO has declared mpox a global public health emergency of international concern due to the severe outbreak in Africa, particularly the DRC. This elevates global awareness and could lead to increased vigilance in the US, but it does not directly impact the CDC's assessment unless there is a substantial domestic threat.

3. **CDC Historical Trends**: Historically, risk assessments by the CDC are cautious and based on evidence of direct threats to the US. Unless there is a substantial increase in domestic transmission or a direct linkage between cases in Africa and the US, a significant risk reassessment is less likely.

4. **Mpox Spread in the US**: There have been no recent cases reported in the US, and the existing assessments indicate a very low likelihood of substantial spread according to the modeled CDC projections. 

5. **International Spread and US Preparedness**: The situation in Africa is concerning, particularly with new variants emerging. However, the logistical and societal pathways for these to affect the US in a significant and rapid way seem unlikely given current travel monitoring and public health measures.

Based on these considerations, the probability that the CDC will increase its assessment to "High" for the general US public before October 1, 2024, is low. This conclusion is supported by current trends, the mitigated risk as perceived by existing health organizations, and historical precedent in their approach to modifying public risk levels.

My Prediction: Between 0.60% and 2.50%, but 1.00% being the most likely. Probability: 1.00%.

2024-10-19 03:29:46,334 - INFO - Run 2:
To determine the likelihood of the CDC's assessment of mpox risk exceeding "High" for the US general public before October 1, 2024, let's evaluate the following factors:

1. **Current CDC Risk Level**: As of the latest CDC assessment on August 14, 2024, the overall risk to the general US population is "VERY LOW." There is no immediate indication that the CDC will raise this assessment to "High" based solely on US-specific factors.

2. **WHO Global Health Emergency Declaration**: The WHO has declared mpox a global public health emergency of international concern due to the severe outbreak in Africa, particularly the DRC. This elevates global awareness and could lead to increased vigilance in the US, but it does not directly impact the CDC's assessment unless there is a substantial domestic threat.

3. **CDC Historical Trends**: Historically, risk assessments by the CDC are cautious and based on evidence of direct threats to the US. Unless there is a substantial increase in domestic transmission or a direct linkage between cases in Africa and the US, a significant risk reassessment is less likely.

4. **Mpox Spread in the US**: There have been no recent cases reported in the US, and the existing assessments indicate a very low likelihood of substantial spread according to the modeled CDC projections. 

5. **International Spread and US Preparedness**: The situation in Africa is concerning, particularly with new variants emerging. However, the logistical and societal pathways for these to affect the US in a significant and rapid way seem unlikely given current travel monitoring and public health measures.

Based on these considerations, the probability that the CDC will increase its assessment to "High" for the general US public before October 1, 2024, is low. This conclusion is supported by current trends, the mitigated risk as perceived by existing health organizations, and historical precedent in their approach to modifying public risk levels.

My Prediction: Between 0.60% and 2.50%, but 1.00% being the most likely. Probability: 1.00%.

2024-10-19 03:29:46,334 - INFO - Run 2:
To determine the likelihood of the CDC's assessment of mpox risk exceeding "High" for the US general public before October 1, 2024, let's evaluate the following factors:

1. **Current CDC Risk Level**: As of the latest CDC assessment on August 14, 2024, the overall risk to the general US population is "VERY LOW." There is no immediate indication that the CDC will raise this assessment to "High" based solely on US-specific factors.

2. **WHO Global Health Emergency Declaration**: The WHO has declared mpox a global public health emergency of international concern due to the severe outbreak in Africa, particularly the DRC. This elevates global awareness and could lead to increased vigilance in the US, but it does not directly impact the CDC's assessment unless there is a substantial domestic threat.

3. **CDC Historical Trends**: Historically, risk assessments by the CDC are cautious and based on evidence of direct threats to the US. Unless there is a substantial increase in domestic transmission or a direct linkage between cases in Africa and the US, a significant risk reassessment is less likely.

4. **Mpox Spread in the US**: There have been no recent cases reported in the US, and the existing assessments indicate a very low likelihood of substantial spread according to the modeled CDC projections. 

5. **International Spread and US Preparedness**: The situation in Africa is concerning, particularly with new variants emerging. However, the logistical and societal pathways for these to affect the US in a significant and rapid way seem unlikely given current travel monitoring and public health measures.

Based on these considerations, the probability that the CDC will increase its assessment to "High" for the general US public before October 1, 2024, is low. This conclusion is supported by current trends, the mitigated risk as perceived by existing health organizations, and historical precedent in their approach to modifying public risk levels.

My Prediction: Between 0.60% and 2.50%, but 1.00% being the most likely. Probability: 1.00%.

2024-10-19 03:30:05,099 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:05,099 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:05,099 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:05,099 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:05,103 - INFO - Run 3:
To assess the likelihood that the CDC's assessment of mpox risk will exceed "High" before October 1, 2024, it's important to consider both the current status and historical precedence.

1. **Base Rates and Historical Context**: Historically, public health emergencies declared by the WHO, such as SARS or H1N1, have led to escalated risk assessments by domestic agencies like the CDC when there is substantial evidence of domestic transmission or significant impact potential. With mpox, the previous peak alert from the WHO was in 2022, but since then, the risk level had been reduced. For the CDC, the risk level to the general US population has historically been assessed as very low to moderate.

2. **Current Evidence and Situation**: Recent news articles, including the CDC's Mpox Rapid Risk Assessment, indicate that as of August 14, 2024, the risk posed to the general US population remains very low, with no new evidence to suggest a significant domestic outbreak. While the WHO has declared a global health emergency, this has been predominantly due to the situation in Africa, where transmission dynamics differ greatly from those in the US.

3. **Extrapolating Current Trends**: No new mpox cases have been reported in the US recently, and the risk remains low according to the CDC. Without domestic transmission or significant new risk factors, it's unlikely the CDC would alter its assessment drastically within the given timeline.

4. **Distinctive Features and Uncertainties**: While the global alert by the WHO increases the need for vigilance, the lack of significant domestic transmission or actionable risk factors, such as direct flights from high-risk regions or lack of necessary data linking the outbreak to US spread, maintains the CDC's low-risk assessment.

5. **Balancing Evidence and Potential Overreaction**: The CDC's current stance, combined with historical actions regarding similar outbreaks, suggests they follow evidence-based adjustments. Rapid changes in risk assessment would require substantial new data or domestic outbreaks, which are currently not indicated.

Taking these into account, along with guiding principles for superforecasting about striking a balance between confidence levels and historical case-based actions, indicates that the CDC's risk assessment is unlikely to exceed "High" before October 1, 2024.

My Prediction: Between 0.10% and 4.00%, but 2.00% being the most likely. Probability: 2.00%.

2024-10-19 03:30:05,103 - INFO - Run 3:
To assess the likelihood that the CDC's assessment of mpox risk will exceed "High" before October 1, 2024, it's important to consider both the current status and historical precedence.

1. **Base Rates and Historical Context**: Historically, public health emergencies declared by the WHO, such as SARS or H1N1, have led to escalated risk assessments by domestic agencies like the CDC when there is substantial evidence of domestic transmission or significant impact potential. With mpox, the previous peak alert from the WHO was in 2022, but since then, the risk level had been reduced. For the CDC, the risk level to the general US population has historically been assessed as very low to moderate.

2. **Current Evidence and Situation**: Recent news articles, including the CDC's Mpox Rapid Risk Assessment, indicate that as of August 14, 2024, the risk posed to the general US population remains very low, with no new evidence to suggest a significant domestic outbreak. While the WHO has declared a global health emergency, this has been predominantly due to the situation in Africa, where transmission dynamics differ greatly from those in the US.

3. **Extrapolating Current Trends**: No new mpox cases have been reported in the US recently, and the risk remains low according to the CDC. Without domestic transmission or significant new risk factors, it's unlikely the CDC would alter its assessment drastically within the given timeline.

4. **Distinctive Features and Uncertainties**: While the global alert by the WHO increases the need for vigilance, the lack of significant domestic transmission or actionable risk factors, such as direct flights from high-risk regions or lack of necessary data linking the outbreak to US spread, maintains the CDC's low-risk assessment.

5. **Balancing Evidence and Potential Overreaction**: The CDC's current stance, combined with historical actions regarding similar outbreaks, suggests they follow evidence-based adjustments. Rapid changes in risk assessment would require substantial new data or domestic outbreaks, which are currently not indicated.

Taking these into account, along with guiding principles for superforecasting about striking a balance between confidence levels and historical case-based actions, indicates that the CDC's risk assessment is unlikely to exceed "High" before October 1, 2024.

My Prediction: Between 0.10% and 4.00%, but 2.00% being the most likely. Probability: 2.00%.

2024-10-19 03:30:05,103 - INFO - Run 3:
To assess the likelihood that the CDC's assessment of mpox risk will exceed "High" before October 1, 2024, it's important to consider both the current status and historical precedence.

1. **Base Rates and Historical Context**: Historically, public health emergencies declared by the WHO, such as SARS or H1N1, have led to escalated risk assessments by domestic agencies like the CDC when there is substantial evidence of domestic transmission or significant impact potential. With mpox, the previous peak alert from the WHO was in 2022, but since then, the risk level had been reduced. For the CDC, the risk level to the general US population has historically been assessed as very low to moderate.

2. **Current Evidence and Situation**: Recent news articles, including the CDC's Mpox Rapid Risk Assessment, indicate that as of August 14, 2024, the risk posed to the general US population remains very low, with no new evidence to suggest a significant domestic outbreak. While the WHO has declared a global health emergency, this has been predominantly due to the situation in Africa, where transmission dynamics differ greatly from those in the US.

3. **Extrapolating Current Trends**: No new mpox cases have been reported in the US recently, and the risk remains low according to the CDC. Without domestic transmission or significant new risk factors, it's unlikely the CDC would alter its assessment drastically within the given timeline.

4. **Distinctive Features and Uncertainties**: While the global alert by the WHO increases the need for vigilance, the lack of significant domestic transmission or actionable risk factors, such as direct flights from high-risk regions or lack of necessary data linking the outbreak to US spread, maintains the CDC's low-risk assessment.

5. **Balancing Evidence and Potential Overreaction**: The CDC's current stance, combined with historical actions regarding similar outbreaks, suggests they follow evidence-based adjustments. Rapid changes in risk assessment would require substantial new data or domestic outbreaks, which are currently not indicated.

Taking these into account, along with guiding principles for superforecasting about striking a balance between confidence levels and historical case-based actions, indicates that the CDC's risk assessment is unlikely to exceed "High" before October 1, 2024.

My Prediction: Between 0.10% and 4.00%, but 2.00% being the most likely. Probability: 2.00%.

2024-10-19 03:30:05,103 - INFO - Run 3:
To assess the likelihood that the CDC's assessment of mpox risk will exceed "High" before October 1, 2024, it's important to consider both the current status and historical precedence.

1. **Base Rates and Historical Context**: Historically, public health emergencies declared by the WHO, such as SARS or H1N1, have led to escalated risk assessments by domestic agencies like the CDC when there is substantial evidence of domestic transmission or significant impact potential. With mpox, the previous peak alert from the WHO was in 2022, but since then, the risk level had been reduced. For the CDC, the risk level to the general US population has historically been assessed as very low to moderate.

2. **Current Evidence and Situation**: Recent news articles, including the CDC's Mpox Rapid Risk Assessment, indicate that as of August 14, 2024, the risk posed to the general US population remains very low, with no new evidence to suggest a significant domestic outbreak. While the WHO has declared a global health emergency, this has been predominantly due to the situation in Africa, where transmission dynamics differ greatly from those in the US.

3. **Extrapolating Current Trends**: No new mpox cases have been reported in the US recently, and the risk remains low according to the CDC. Without domestic transmission or significant new risk factors, it's unlikely the CDC would alter its assessment drastically within the given timeline.

4. **Distinctive Features and Uncertainties**: While the global alert by the WHO increases the need for vigilance, the lack of significant domestic transmission or actionable risk factors, such as direct flights from high-risk regions or lack of necessary data linking the outbreak to US spread, maintains the CDC's low-risk assessment.

5. **Balancing Evidence and Potential Overreaction**: The CDC's current stance, combined with historical actions regarding similar outbreaks, suggests they follow evidence-based adjustments. Rapid changes in risk assessment would require substantial new data or domestic outbreaks, which are currently not indicated.

Taking these into account, along with guiding principles for superforecasting about striking a balance between confidence levels and historical case-based actions, indicates that the CDC's risk assessment is unlikely to exceed "High" before October 1, 2024.

My Prediction: Between 0.10% and 4.00%, but 2.00% being the most likely. Probability: 2.00%.

2024-10-19 03:30:23,830 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:23,830 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:23,830 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:23,830 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:23,830 - INFO - Question: Will the CDC's assessment of the risk posed by mpox to the US general public exceed "High" before October 1, 2024?
2024-10-19 03:30:23,831 - INFO - Run 4:
To determine the likelihood that the CDC's assessment of the risk posed by mpox to the US general public will exceed "High" before October 1, 2024, we need to conduct a structured analysis:

1. **Reference Classes and Base Rates**: Historically, the CDC's risk assessment for mpox in the US has generally not exceeded "High," given the relatively contained nature of previous outbreaks and the specific risk populations identified, such as men who have sex with men and people with multiple partners. This suggests a low starting probability.

2. **Current Events and Distinctive Features**: 
   - The current situation involves a new variant known as clade 1b, reported as more transmissible and possibly more severe. However, current news indicates that the US CDC assesses the risk to the US general public as "VERY LOW" concerning this situation.
   - Despite the WHO declaring a global public health emergency, the risk remains primarily concentrated in the Democratic Republic of Congo and spreading within certain African regions, not the US.

3. **Factors Lowering Probability**:
   - The US has extensive vaccine coverage, with the Jynneos vaccine known to be effective against mpox and accessible to high-risk populations.
   - The CDC's current assessment explicitly states a "very low" risk to the general public, indicating a limited chance of a dramatic reassessment.
   - There is no current report of significant, sustained transmission or major public health disruptions related to mpox in the US.

4. **Factors Potentially Raising Probability**:
   - If the variant demonstrates increased virulence or transmission and becomes widespread, it could prompt a higher risk assessment, especially if linked to international travel cases.
   - Limited immediate data can sometimes change within weeks, impacting forecasts relying on static data.

5. **Balancing Evidence and Commandments of Superforecasting**:
   - We must avoid overreacting to evidence from Africa without US-specific implications. 
   - Consider that global declarations don’t directly translate to a risk change in the US due to different context and public health measures.
   - Balance inside views (current US status and intelligence) with international insights (global declarations and risks).

Therefore, aligning these insights with historical base rates and the evident risk factors, both external and internal, it's reasonable to assign a conservative forecast that the CDC will not raise the US general public risk assessment to above "High."

My Prediction: Between 0.10% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-19 03:30:23,831 - INFO - Run 4:
To determine the likelihood that the CDC's assessment of the risk posed by mpox to the US general public will exceed "High" before October 1, 2024, we need to conduct a structured analysis:

1. **Reference Classes and Base Rates**: Historically, the CDC's risk assessment for mpox in the US has generally not exceeded "High," given the relatively contained nature of previous outbreaks and the specific risk populations identified, such as men who have sex with men and people with multiple partners. This suggests a low starting probability.

2. **Current Events and Distinctive Features**: 
   - The current situation involves a new variant known as clade 1b, reported as more transmissible and possibly more severe. However, current news indicates that the US CDC assesses the risk to the US general public as "VERY LOW" concerning this situation.
   - Despite the WHO declaring a global public health emergency, the risk remains primarily concentrated in the Democratic Republic of Congo and spreading within certain African regions, not the US.

3. **Factors Lowering Probability**:
   - The US has extensive vaccine coverage, with the Jynneos vaccine known to be effective against mpox and accessible to high-risk populations.
   - The CDC's current assessment explicitly states a "very low" risk to the general public, indicating a limited chance of a dramatic reassessment.
   - There is no current report of significant, sustained transmission or major public health disruptions related to mpox in the US.

4. **Factors Potentially Raising Probability**:
   - If the variant demonstrates increased virulence or transmission and becomes widespread, it could prompt a higher risk assessment, especially if linked to international travel cases.
   - Limited immediate data can sometimes change within weeks, impacting forecasts relying on static data.

5. **Balancing Evidence and Commandments of Superforecasting**:
   - We must avoid overreacting to evidence from Africa without US-specific implications. 
   - Consider that global declarations don’t directly translate to a risk change in the US due to different context and public health measures.
   - Balance inside views (current US status and intelligence) with international insights (global declarations and risks).

Therefore, aligning these insights with historical base rates and the evident risk factors, both external and internal, it's reasonable to assign a conservative forecast that the CDC will not raise the US general public risk assessment to above "High."

My Prediction: Between 0.10% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-19 03:30:23,831 - INFO - Run 4:
To determine the likelihood that the CDC's assessment of the risk posed by mpox to the US general public will exceed "High" before October 1, 2024, we need to conduct a structured analysis:

1. **Reference Classes and Base Rates**: Historically, the CDC's risk assessment for mpox in the US has generally not exceeded "High," given the relatively contained nature of previous outbreaks and the specific risk populations identified, such as men who have sex with men and people with multiple partners. This suggests a low starting probability.

2. **Current Events and Distinctive Features**: 
   - The current situation involves a new variant known as clade 1b, reported as more transmissible and possibly more severe. However, current news indicates that the US CDC assesses the risk to the US general public as "VERY LOW" concerning this situation.
   - Despite the WHO declaring a global public health emergency, the risk remains primarily concentrated in the Democratic Republic of Congo and spreading within certain African regions, not the US.

3. **Factors Lowering Probability**:
   - The US has extensive vaccine coverage, with the Jynneos vaccine known to be effective against mpox and accessible to high-risk populations.
   - The CDC's current assessment explicitly states a "very low" risk to the general public, indicating a limited chance of a dramatic reassessment.
   - There is no current report of significant, sustained transmission or major public health disruptions related to mpox in the US.

4. **Factors Potentially Raising Probability**:
   - If the variant demonstrates increased virulence or transmission and becomes widespread, it could prompt a higher risk assessment, especially if linked to international travel cases.
   - Limited immediate data can sometimes change within weeks, impacting forecasts relying on static data.

5. **Balancing Evidence and Commandments of Superforecasting**:
   - We must avoid overreacting to evidence from Africa without US-specific implications. 
   - Consider that global declarations don’t directly translate to a risk change in the US due to different context and public health measures.
   - Balance inside views (current US status and intelligence) with international insights (global declarations and risks).

Therefore, aligning these insights with historical base rates and the evident risk factors, both external and internal, it's reasonable to assign a conservative forecast that the CDC will not raise the US general public risk assessment to above "High."

My Prediction: Between 0.10% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-19 03:30:23,831 - INFO - Run 4:
To determine the likelihood that the CDC's assessment of the risk posed by mpox to the US general public will exceed "High" before October 1, 2024, we need to conduct a structured analysis:

1. **Reference Classes and Base Rates**: Historically, the CDC's risk assessment for mpox in the US has generally not exceeded "High," given the relatively contained nature of previous outbreaks and the specific risk populations identified, such as men who have sex with men and people with multiple partners. This suggests a low starting probability.

2. **Current Events and Distinctive Features**: 
   - The current situation involves a new variant known as clade 1b, reported as more transmissible and possibly more severe. However, current news indicates that the US CDC assesses the risk to the US general public as "VERY LOW" concerning this situation.
   - Despite the WHO declaring a global public health emergency, the risk remains primarily concentrated in the Democratic Republic of Congo and spreading within certain African regions, not the US.

3. **Factors Lowering Probability**:
   - The US has extensive vaccine coverage, with the Jynneos vaccine known to be effective against mpox and accessible to high-risk populations.
   - The CDC's current assessment explicitly states a "very low" risk to the general public, indicating a limited chance of a dramatic reassessment.
   - There is no current report of significant, sustained transmission or major public health disruptions related to mpox in the US.

4. **Factors Potentially Raising Probability**:
   - If the variant demonstrates increased virulence or transmission and becomes widespread, it could prompt a higher risk assessment, especially if linked to international travel cases.
   - Limited immediate data can sometimes change within weeks, impacting forecasts relying on static data.

5. **Balancing Evidence and Commandments of Superforecasting**:
   - We must avoid overreacting to evidence from Africa without US-specific implications. 
   - Consider that global declarations don’t directly translate to a risk change in the US due to different context and public health measures.
   - Balance inside views (current US status and intelligence) with international insights (global declarations and risks).

Therefore, aligning these insights with historical base rates and the evident risk factors, both external and internal, it's reasonable to assign a conservative forecast that the CDC will not raise the US general public risk assessment to above "High."

My Prediction: Between 0.10% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

2024-10-19 03:30:23,831 - INFO - Run 4:
To determine the likelihood that the CDC's assessment of the risk posed by mpox to the US general public will exceed "High" before October 1, 2024, we need to conduct a structured analysis:

1. **Reference Classes and Base Rates**: Historically, the CDC's risk assessment for mpox in the US has generally not exceeded "High," given the relatively contained nature of previous outbreaks and the specific risk populations identified, such as men who have sex with men and people with multiple partners. This suggests a low starting probability.

2. **Current Events and Distinctive Features**: 
   - The current situation involves a new variant known as clade 1b, reported as more transmissible and possibly more severe. However, current news indicates that the US CDC assesses the risk to the US general public as "VERY LOW" concerning this situation.
   - Despite the WHO declaring a global public health emergency, the risk remains primarily concentrated in the Democratic Republic of Congo and spreading within certain African regions, not the US.

3. **Factors Lowering Probability**:
   - The US has extensive vaccine coverage, with the Jynneos vaccine known to be effective against mpox and accessible to high-risk populations.
   - The CDC's current assessment explicitly states a "very low" risk to the general public, indicating a limited chance of a dramatic reassessment.
   - There is no current report of significant, sustained transmission or major public health disruptions related to mpox in the US.

4. **Factors Potentially Raising Probability**:
   - If the variant demonstrates increased virulence or transmission and becomes widespread, it could prompt a higher risk assessment, especially if linked to international travel cases.
   - Limited immediate data can sometimes change within weeks, impacting forecasts relying on static data.

5. **Balancing Evidence and Commandments of Superforecasting**:
   - We must avoid overreacting to evidence from Africa without US-specific implications. 
   - Consider that global declarations don’t directly translate to a risk change in the US due to different context and public health measures.
   - Balance inside views (current US status and intelligence) with international insights (global declarations and risks).

Therefore, aligning these insights with historical base rates and the evident risk factors, both external and internal, it's reasonable to assign a conservative forecast that the CDC will not raise the US general public risk assessment to above "High."

My Prediction: Between 0.10% and 5.00%, but 2.50% being the most likely. Probability: 2.50%.

